Long-Term Assets: The sum of all assets classified as non-current.
Apimeds Pharmaceuticals US, Inc. (APUS) had Long-Term Assets of $116.95M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-20.17M |
|
-- |
|
-- |
|
$6.28M |
|
$-6.28M |
|
$-13.89M |
|
$-20.17M |
|
$-8.70M |
|
$-20.17M |
|
$-20.17M |
|
$-20.17M |
|
$-8.70M |
|
$-6.28M |
|
$-6.26M |
|
1.71M |
|
1.71M |
|
$-11.77 |
|
$-11.77 |
|
| Balance Sheet Financials | |
$10.68M |
|
$0.05M |
|
|
Long-Term Assets |
$116.95M |
$127.62M |
|
$21.07M |
|
-- |
|
$0.10M |
|
$21.18M |
|
$106.45M |
|
$-10.29M |
|
$106.45M |
|
1.51M |
|
| Cash Flow Statement Financials | |
$-7.73M |
|
$1.99M |
|
$4.39M |
|
$9.64M |
|
$8.28M |
|
$-1.36M |
|
$0.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.51 |
|
-- |
|
-- |
|
-- |
|
0.14 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.74M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-18.95% |
|
196.07% |
|
-15.81% |
|
-18.95% |
|
$70.54 |
|
$-4.52 |
|
$-4.52 |
|